Plant · Scientific monograph
Ginkgo biloba
Ginkgo / Maidenhair tree
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Cognitive Function Research, Neurological & Cognitive Research, Cardiovascular System
Research overview
Historical use
One of the oldest living tree species on Earth (>200 million years old), revered in China for over 5,000 years as 'yin xing' (silver apricot). Leaves and seeds used in Traditional Chinese Medicine for respiratory conditions, urinary dysfunction, and memory decline. Introduced to Western pharmacology in the 1960s; the standardised extract EGb 761 was developed by Willmar Schwabe GmbH and remains the most extensively studied phytomedicine in Europe.
Modern research context
EGb 761 (standardised to 24% flavonol glycosides and 6% terpene lactones) is approved in Germany for symptomatic treatment of dementia and peripheral arterial disease. A 2025 meta-analysis of pooled RCT data demonstrates statistically significant benefits of EGb 761 for cognition, activities of daily living, and clinical improvement in dementia patients with a history of cerebral infarction, with a safety profile comparable to placebo [10]. Network meta-analysis confirms Ginkgo biloba among the most effective plant compounds for learning, memory, and executive function in healthy older adults [8]. A 2026 randomised clinical trial evaluated Ginkgo biloba extract for prevention of posterior capsule opacification following cataract surgery, extending its evidence base beyond neurological applications [7].
Adverse effects
GI upset (nausea, diarrhoea), headache, dizziness, and palpitations are common. Skin hypersensitivity reactions are possible. Rarely, spontaneous bleeding events including subdural haematoma and vitreous haemorrhage have been reported in case series. Ginkgolic acids in crude preparations are nephrotoxic and potentially carcinogenic; pharmaceutical extracts limit these to <5 ppm. Herb-drug interactions at the CYP450 level can precipitate adverse drug reactions through altered drug plasma levels [11].
Contraindications
Contraindicated with anticoagulants (warfarin, heparin) and antiplatelet drugs (aspirin, clopidogrel, NSAIDs) due to documented INR alteration and additive bleeding risk [4, 13]. Discontinue at least 36 hours before surgery. Caution with antiepileptics metabolised via CYP2C9, including phenytoin [6]. Avoid in patients with a history of seizures. Avoid unpurified leaf preparations containing elevated ginkgolic acids.
Clinical and phytochemical data
Used part
Leaf (standardised extract EGb 761); seed (limited therapeutic use — nephrotoxic in raw form)
Primary active compounds
Ginkgo flavonol glycosides (quercetin-3-rutinoside, kaempferol-3-rutinoside, isorhamnetin glycosides)
Ginkgolides A, B, C, J (diterpene lactones)
Bilobalide (sesquiterpene lactone)
Ginkgetin (biflavonoid)
Ginkgolic acids (alkyl/alkenyl phenols — limited to <5 ppm in EGb 761)
Proanthocyanidins
Mechanism of action
Ginkgo biloba enhances cerebral perfusion and facilitates synaptic plasticity through convergent monoaminergic and neurotrophic pathways, with documented inhibitory activity at monoamine oxidase A (MAO-A) and MAO-B [3]. The biflavonoid ginkgetin exerts pleiotropic anti-inflammatory activity through inhibition of NF-κB and suppression of pro-inflammatory cytokines, alongside antioxidant and antifibrotic effects via multi-target signalling modulation [9]. Ginkgolide B acts as a selective antagonist at the platelet-activating factor (PAF) receptor, inhibiting platelet aggregation. Flavonol glycosides scavenge reactive oxygen species and upregulate Nrf2/HO-1 antioxidant defence genes, protecting against oxidative neuronal damage [3]. The extract modulates CYP1A2, CYP2C9, CYP2D6, and CYP3A4 activity, with clinically relevant implications for co-administered drugs [1].
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Preclinical studies of Ginkgo biloba semen-derived components (GK-A, GK-2, Eucomic acid) in rats demonstrate rapid gastrointestinal absorption following oral administration [5]. Flavonol glycosides are hydrolysed in the gut by intestinal beta-glucosidases to their aglycones (quercetin, kaempferol, isorhamnetin) prior to systemic absorption; this biotransformation step is modulated by the intestinal microbiome and may affect bioavailability in dysbiotic states [2].
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Rat pharmacokinetic studies of Ginkgo semen extract components demonstrate wide tissue distribution following oral dosing, with detection in brain, liver, kidney, and plasma [5]. Lipophilic terpene lactones are predicted to cross the blood-brain barrier based on animal tissue distribution data, consistent with the clinically observed central nervous system effects of EGb 761 [3].
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Rat liver microsomal studies of Ginkgo semen extract components indicate slow hepatic biotransformation, with CYP450 enzymes contributing only minimally as primary metabolising enzymes for the major active constituents [5]. However, at the whole-extract level, Ginkgo biloba modulates CYP1A2, CYP2C9, CYP2D6, and CYP3A4 activity in a clinically significant manner [1, 2], with the potential to alter plasma levels of co-administered substrates.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Preclinical pharmacokinetic profiling of Ginkgo semen components in rats identified renal excretion as the primary elimination route, with elimination kinetics characterised across major tissues [5]. Exact half-life values for the standardised leaf extract EGb 761 components in humans have not been captured in the peer-reviewed literature retrieved for this monograph.
Safety and interactions
Drug interactions
Anticoagulants (warfarin): Ginkgo biloba is documented to alter INR in patients on warfarin, constituting a clinically significant interaction requiring vigilant therapeutic monitoring [4]. Antiepileptics (phenytoin): A 2025 systematic review identified Ginkgo biloba as a clinically relevant interaction partner for phenytoin, with CYP2C9 modulation as the primary mechanism [6]. CYP450 substrates (CYP1A2, CYP2C9, CYP2D6, CYP3A4): Ginkgo biloba significantly modulates all four major CYP isoforms, affecting pharmacokinetics of co-administered drugs across multiple therapeutic classes [1, 2]. Antithrombotic agents (aspirin, clopidogrel, NSAIDs): Additive antiplatelet activity documented, with increased bleeding risk when combined with antithrombotic therapies [13]. CYP450-mediated herb-drug interactions can precipitate adverse events through toxic elevation of drug plasma concentrations [11].
Toxicity
Ginkgolic acids are nephrotoxic and genotoxic at elevated concentrations; pharmaceutical EGb 761 extract limits these to <5 ppm. Ginkgotoxin (4'-O-methylpyridoxine) present in seeds is seizurogenic and pyridoxine-responsive; leaf extracts contain minimal amounts. Ginkgetin demonstrates a broad preclinical safety profile across anti-inflammatory and antifibrotic applications [9]. High-dose chronic rodent studies (NTP) identified hepatocellular adenoma; clinical relevance in humans at standard therapeutic doses remains uncertain.
Special precautions
Pregnancy
Insufficient human safety data available. Ginkgolic acids are potentially teratogenic in animal models. Avoid during pregnancy.
Lactation
Excretion into breast milk is unknown. Avoid due to insufficient safety data.
Hepatic impairment
CYP1A2, CYP2C9, CYP2D6, and CYP3A4 are hepatically expressed; impaired hepatic metabolism is expected in liver disease, increasing risk of drug interactions [1, 2]. No formal dose adjustment studies have been conducted. Use with caution.
Renal impairment
Renal excretion is the primary elimination route for active metabolites based on preclinical data [5]. Accumulation of active constituents is possible in severe renal impairment. No formal dose adjustment guidelines are established.
Sources and references
- [1] - Shanaida M, Oleshchuk O, Shevchuk O et al., "Herbal Medicines and Drugs Interactions: Cytochrome P450 Responsibility", Current Medicinal Chemistry, 2026, PMID: 41764614
- [2] - Khan A, Abdulaziz Al-Hamoud G, Amina M et al., "Role of herbal extracts in modulating drug metabolism: implications for pharmacokinetics, enzyme regulation, and therapeutic outcome", Drug Metabolism Reviews, 2026, PMID: 41392934
- [3] - Li X, Li X, Li Y et al., "Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways", Frontiers in Nutrition, 2026, PMID: 41909050
- [4] - Tolou-Ghamari Z, "Interactions Among Drugs, Food, Beverages, Alcohol, Herbs, Phytochemicals, Nutraceuticals, and Micronutrients: A Current and Updated Review", Cardiovascular & Hematological Agents in Medicinal Chemistry, 2026, PMID: 42136239
- [5] - Lu Z, Zhao J, Xiao W et al., "Pharmacokinetics, tissue distribution, in vivo metabolism and liver microsomal metabolism of GK-A, GK-2 and Eucomic acid in rats", Journal of Ethnopharmacology, 2026, PMID: 41207346
- [6] - Orellana-Paucar AM, Mosquera-Lopez ET, Bustamante-Alvarez NM et al., "Optimizing phenytoin therapy: a systematic review of clinically relevant food and herb interactions", Frontiers in Pharmacology, 2025, PMID: 41560756
- [7] - Amiri AA, Rad HA et al., "Effect of Ginkgo biloba extracts in the prevention of posterior capsule opacification after cataract surgery: A randomized clinical trial", Oman Journal of Ophthalmology, 2026, PMID: 41930010
- [8] - Feng X, Fan S, Wei F, "The effect of plant active substances on cognitive function in healthy older adults: a systematic review and network meta-analysis", Frontiers in Pharmacology, 2025, PMID: 41640686
- [9] - Sun Z, Rao Z, Lu Y, Zheng X, Zheng L, "Ginkgetin: A Promising Multitarget Agent for Diverse Diseases", Biomolecules, 2026, PMID: 42072610
- [10] - Feng JX, Zheng MQ, Tian X et al., "Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction — meta-analysis of pooled data from randomised clinical trials", Frontiers in Neurology, 2025, PMID: 41908799
- [11] - Bukowska B, Grzegorowska A, Szczerkowska-Majchrzak E et al., "Hazardous Interactions Between Food, Herbs, and Drugs in the First Stage of Biotransformation: Case Reports of Adverse Drug Interactions in Humans", International Journal of Molecular Sciences, 2025, PMID: 40507996
- [12] - Pena E, Del Rio A, Flores S, "Systematic review and meta-analysis of antioxidant treatment in patients with acute mountain sickness induced by high altitude exposure", Frontiers in Physiology, 2026, PMID: 41878732
- [13] - Dobre MZ, Virgolici B, Doicin IC et al., "Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks", International Journal of Molecular Sciences, 2025, PMID: 41155474